Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...
Investor's Business Daily on MSN
Merck stock zooms closer to a breakout on 'a new chapter' in cancer
Merck stock popped early Friday after European officials recommended approving its combination for a form of bladder cancer.
Keytruda plus chemotherapy is now a first-line treatment for pleural mesothelioma, replacing chemotherapy alone as the standard of care. The KEYNOTE-483 trial showed significant improvements in ...
Zacks Investment Research on MSN
MRK stock gains after CHMP backs Keytruda combo for bladder cancer
Shares of Merck MRK rose nearly 6% on Friday after the company announced that the EMA’s Committee for Medicinal Products for ...
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive ...
The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved Keytruda ...
Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology ...
Keytruda is an immunotherapy drug that is prescribed to cancer patients and is used to treat different types of cancer. It was first approved by the FDA in 2014 for the treatment of advanced or ...
A statistically significant improvement in progression free survival was observed with pembrolizumab plus chemotherapy in both the dMMR and pMMR populations. The Food and Drug Administration (FDA) has ...
EU CHMP recommends approval of Merck’s Keytruda plus Padcev as perioperative treatment for adults with cisplatin-ineligible resectable muscle-invasive bladder cancer: Rahway, Ne ...
At five years, KEYTRUDA plus LENVIMA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy ...
Merck & Co Inc (NYSE:MRK) on Thursday said the Phase 3 KEYNOTE-B96 trial (also known as ENGOT-ov65), met its primary endpoint of progression-free survival (PFS) for platinum-resistant recurrent ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results